Clinical Trials Study
Copyright ©The Author(s) 2017.
World J Gastroenterol. Apr 14, 2017; 23(14): 2601-2612
Published online Apr 14, 2017. doi: 10.3748/wjg.v23.i14.2601
Table 6 Relationship of the adenocarcinomas’ clinicopathological parameters and ROR2 and WNT5a expression with average survival
GroupingNumber of cases, nAverage survival in moχ2P value
Sex
Male269.58 (3-24)2.5670.109
Female5411.30 (3-24)
Age, yr
≤ 451610.81 (4-24)0.0030.956
> 456410.72 (3-24)
Degree of differentiation
High2715.07 (5-24)32.5010.000
Moderate2510.60 (4-24)
Poor286.68 (3-14)
Maximal diameter of the mass, cm
≤ 35013.70 (6-24)68.2830.000
> 3305.80 (3-10)
Gallstones
No4210.19 (3-24)0.2460.620
Yes3811.34 (4-24)
TNM stage
I + II2118.96 (5-24)105.8250.000
III389.29 (6-15)
IV215.14 (3-7)
Lymph node metastasis
No3016.27 (4-24)42.3720.000
Yes507.42 (3-14)
Invasion of the surrounding tissue
No3116.68 (7-24)55.5350.000
Yes496.98 (3-11)
Surgical procedure
Radical2618.31 (10-24)113.1410.000
Palliative288.64 (6-11)
Unresected265.42 (3-9)
ROR2
-2915.93 (6-24)32.9940.000
+517.78 (3-19)
WNT5a
-3115.48 (4-24)31.6540.002
+497.74 (3-18)